[1]陆一峰,王 祁,何忠明.构建基于控制营养状况评分的列线图预测肝细胞癌TACE治疗患者预后[J].介入放射学杂志,2023,32(12):1190-1196.
　LU Yifeng,WANG Qi,HE Zhongming..Construction of a nomogram based on controlling nutritional status score for predicting the prognosis of hepatocellular carcinoma patients after receiving TACE[J].journal interventional radiology,2023,32(12):1190-1196.
点击复制

构建基于控制营养状况评分的列线图预测肝细胞癌TACE治疗患者预后()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年12
页码:
1190-1196
栏目:
肿瘤介入
出版日期:
2024-01-02

文章信息/Info

Title:
Construction of a nomogram based on controlling nutritional status score for predicting the prognosis of hepatocellular carcinoma patients after receiving TACE
作者:
陆一峰;  王 祁;  何忠明
Author(s):
LU Yifeng;  WANG Qi;  HE Zhongming.
Department of Interventional Radiology， Third Affiliated Hospital of Soochow University （Changzhou Municipal First People’s Hospital）， Changzhou， Jiangsu Province 213000， China
关键词:
【关键词】 肝细胞癌;  经导管动脉化疗栓塞术;  控制营养状况评分;  列线图;  预后预测
文献标志码:
A
摘要:
【摘要】 目的 探讨控制营养状况（CONUT）评分对经导管动脉化疗栓塞术（TACE）治疗肝细胞癌（HCC）患者的预后意义，并构建整合多种预后因素的列线图模型，以帮助临床医师准确预测个体预后。方法 回顾性分析2017年1月至2020年6月于苏州大学附属第三医院接受TACE治疗的155例原发性HCC患者临床资料。通过受试者工作特征曲线（ROC）分析CONUT评分最佳截断值，Kaplan-Meier曲线分析其预后意义。采用单变量、多变量Cox生存分析确定接受TACE治疗HCC患者独立预后因素。以多变量分析的显著变量构建列线图模型，使用一致性指数（C-index）评价其预测TACE治疗HCC患者总生存期（OS）能力。绘制校准曲线评价预测概率与实际OS结局间的一致性。结果 CONUT评分预测OS最佳截断值为4，AUC值为0.766（95%CI=0.691～0.841）。高CONUT评分（≥4）组患者肿瘤直径更大（P=0.014），血清AFP水平更高（P=0.002），肝储备功能（P＜0.01）和TACE治疗反应（P＜0.01）更差，中位OS更短（P＜0.01）。Child-Pugh分级、肿瘤最大直径、血清AFP水平、BCLC分期、TACE治疗反应及CONUT评分（均P＜0.05）是TACE治疗后HCC患者OS的独立预测因素。基于以上变量构建列线图模型，其C-index为0.785（95%CI=0.691～0.879）。校准曲线显示模型预测概率与实际概率间具有高度一致性。结论 CONUT评分是评价接受TACE治疗HCC患者预后的简单可行工具。基于肿瘤生物学特征、TACE治疗反应及CONUT评分的列线图模型对HCC患者具有可靠的预后预测能力，值得进一步推广验证。

参考文献/References:

［1］ Heimbach JK， Kulik LM， Finn RS， et al. AASLD guidelines for the treatment of hepatocellular carcinoma［J］. Hepatology， 2018， 67： 358- 380.
［2］ 中华人民共和国国家卫生健康委员会．原发性肝癌诊疗指南（2022年版）［J］． 传染病信息， 2022， 35：1- 26．
［3］ Ebeling Barbier C， Heindryckx F， Lennernas H. Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma［J］. Int J Mol Sci， 2021， 22： 13051.
［4］ Zhong BY， Jin ZC， Chen JJ， et al. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma［J］. J Clin Transl Hepatol， 2023， 11： 480- 489.
［5］ Gillmore R， Stuart S， Kirkwood A， et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization［J］. J Hepatol， 2011， 55： 1309- 1316.
［6］ Waked I， Berhane S， Toyoda H， et al. Transarterial chemo- embolisation of hepatocellular carcinoma： impact of liver function and vascular invasion［J］. Br J Cancer， 2017， 116： 448- 454.
［7］ Tian M， Zhang X， Huang G， et al. Alpha- fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization［J］. Abdom Radiol（NY）， 2019， 44： 3304- 3311.
［8］ Ji K， Zhu H， Wu W， et al. Tumor response and nomogram- based prognostic stratification for hepatocellular carcinoma after drug- eluting beads transarterial chemoembolization［J］. J Hepatocell Carcinoma， 2022， 9： 537- 551.
［9］ Müller L， Hahn F， Mahringer- Kunz A， et al. Immunonutritive scoring in patients with hepatocellular carcinoma undergoing transarterial chemoembolization： prognostic nutritional index or controlling nutritional status score?［J］. Front Oncol， 2021， 11： 696183.
［10］ Roth G， Teyssier Y， Benhamou M， et al. Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans- arterial（chemo）- embolization［J］. World J Gastroenterol， 2022， 28： 5324- 5337.
［11］ Lin ZX， Ruan DY， Jia CC， et al. Controlling nutritional status （CONUT） score- based nomogram to predict overall survival of patients with HBV- associated hepatocellular carcinoma after curative hepatectomy［J］. Clin Transl Oncol， 2020， 22： 370- 380.
［12］ Peng W， Yao M， Zou K， et al. Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma： a retrospective study［J］. BMC Surg， 2021， 21： 338.
［13］ Tsunematsu M，Haruki K， Fujiwara Y， et al. Preoperative controlling nutritional status （CONUT） score predicts long- term outcomes in patients with non- B non- C hepatocellular carcinoma after curative hepatic resection［J］. Langenbecks Arch Surg， 2021， 406： 99- 107.
［14］ Ignacio de Ulibarri J， Gonzalez- Madrono A， de Villar NGP， et al. CONUT： a tool for controlling nutritional status. First validation in a hospital population［J］. Nutr Hosp， 2005， 20： 38- 45.
［15］ 中国医师协会介入医师分会临床诊疗指南专委会．中国肝细胞癌经动脉化疗栓塞（TACE）治疗临床实践指南（2021年版）［J］．中华医学杂志，2021，101：1848- 1862．
［16］ Llovet JM， Lencioni R. mRECIST for HCC： performance and novel refinements［J］. J Hepatol， 2020， 72： 288- 306.
［17］ Ho SY， Hsu CY， Liu PH， et al. Albumin- bilirubin （ALBI） grade- based nomogram for patients with hepatocellular carcinoma undergoing transarterial chemoembolization［J］. Dig Dis Sci， 2021， 66： 1730- 1738.
［18］ 张司马康，周春高，施海彬，等．骨骼肌质量指数对TACE治疗肝癌的预测价值［J］． 介入放射学杂志， 2022， 31：1170- 1173．
［19］ Zhang YQ， Jiang LJ， Wen J， et al. Comparison of α- fetoprotein criteria and modified response evaluation criteria in solid tumors for the prediction of overall survival of patients with hepatocellular carcinoma after transarterial chemoembolization［J］. J Vasc Interv Radiol ， 2018， 29： 1654- 1661.
［20］ Cun J， Xu Y， Li W， et al. Analysis of factors affecting the prognosis of transcatheter arterial chemoembolization for hepatitis B- related hepatocellular carcinoma［J］. J Interv Med， 2021， 4： 66- 70.
［21］ Chon YE， Park H， Hyun HK， et al. Development of a new nomogram including neutrophil- to- lymphocyte ratio to predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization［J］. Cancers（Basel）， 2019， 11：509.
［22］ Li J， Li C， Zhu G， et al. A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization： a tool for retreatment decision making［J］. Ann Transl Med， 2023， 11： 68.
［23］ Shimose S， Kawaguchi T， Iwamoto H， et al. Controlling nutritional status（CONUT） score is associated with overall survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib： a multicenter cohort study［J］. Nutrients，2020，12：1076.
［24］ Tamai Y， Iwasa M， Eguchi A， et al. The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment［J］. Eur J Gastroenterol Hepatol， 2022，34： 1269- 1276.
［25］ European Association for the Study of the Liver. EASL clinical practice guidelines： management of hepatocellular carcinoma［J］. J Hepatol， 2018， 69： 182- 236.
［26］ Marrero JA， Kulik LM， Sirlin CB， et al. Diagnosis， staging， and management of hepatocellular carcinoma： 2018 practice guidance by the American association for the study of liver diseases［J］. Hepatology， 2018， 68： 723- 750.
［27］ Prajapati HJ， Spivey JR， Hanish SI， et al. mRECIST and EASL responses at early time point by contrast- enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma（HCC） treated by doxorubicin drug- eluting beads transarterial chemoembolization（DEB TACE）［J］. Ann Oncol， 2013， 24： 965- 973.
［28］ Jung J， Joo JH， Kim SY， et al. Radiologic response as a prognostic factor in advanced hepatocellular carcinoma with macroscopic vascular invasion after transarterial chemoembolization and radiotherapy［J］. Liver Cancer， 2022， 11： 152- 161.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(12):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(12):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(12):206.
[4]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(12):621.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(12):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(12):974.
[7]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(12):78.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(12):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(12):520.
[10]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(12):769.
[11]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(12):406.
[12]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(12):1114.
[13]刘璐璐,邵国良,庞佩佩.磁共振弥散加权和动态增强成像评价晚期肝癌TACE术疗效研究进展 [J].介入放射学杂志,2017,(08):756.
　LIU Lulu,SHAO Guoliang,PANG Peipei.Application of diffusion- weighted and dynamic contrast- enhanced MRI in evaluating the curative effect of TACE for advanced hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(12):756.
[14]中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南[J].介入放射学杂志,2018,27(12):1117.
　Chinese College of Interventionalists,Chinese Medical Doctor Association.Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J].journal interventional radiology,2018,27(12):1117.
[15]张 申,张 磊,仲斌演,等.“TACE抵抗/失败”——需要全面认识[J].介入放射学杂志,2020,29(08):743.
　ZHANG Shen,ZHANG Lei,ZHONG Binyan,et al.Comprehensive understanding of the concept and connotation of “TACE- failure/refractoriness”[J].journal interventional radiology,2020,29(12):743.
[16]刘 嵘,程永德,王小林,等.中国肝细胞癌TACE治疗的历史、现状和展望 ——纪念我国介入放射学奠基人林贵教授[J].介入放射学杂志,2022,31(08):743.
　LIU Rong,CHENG Yongde,WANG Xiaolin,et al.The history, status and future of transarterial chemoembolization of hepatocellular carcinoma in China: in memory of Professor Gui Lin, the founder of interventional radiology in China[J].journal interventional radiology,2022,31(12):743.
[17]夏子聪,赵 辉.改善经导管动脉化疗栓塞术疗效的临床及基础研究进展[J].介入放射学杂志,2023,32(07):705.
　XIA Zicong,ZHAO Hui..Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization[J].journal interventional radiology,2023,32(12):705.
[18]管清龙,陈海波,刘成龙,等.体素内不相干运动-弥散加权成像评价不同栓塞材料经动脉化疗栓塞治疗肝细胞癌效果及预后[J].介入放射学杂志,2024,33(02):140.
　GUAN Qinglong,CHNE Haibo,LIU Chenglong,et al.The application of IVIM-DWI in evaluating the efficacy and prognosis of TACE using different embolization materials for hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):140.
[19]隰子涵,杨永波,邵国良.MRI和临床危险因素对中晚期肝细胞癌首次D-TACE近期疗效预测价值分析[J].介入放射学杂志,2024,33(04):376.
　XI Zihan,YANG Yongbo,SHAO Guoliang..The value of MRI and clinical risk factors in predicting the short-term efficacy of initial D-TACE in patients with intermediate and advanced stage hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):376.

备注/Memo

备注/Memo:
（收稿日期：2023- 04- 14）
（本文编辑：谷 珂）
更新日期/Last Update: 2024-01-02